Marta Magatti

TL;DR: The aim of this review is to summarize and provide the state of the art of research in this field, addressing aspects such as cell isolation protocols and characteristics of these cells, as well as providing preliminary indications of the possibilities for use ofThese cells in future clinical applications.

TL;DR: The revelation that human amniotic mesenchyme possesses cell populations with both suppressive and stimulatory properties sheds additional light on the immunomodulatory functions of this tissue and may contribute to the clarification of some ongoing controversies associated with mesenchymal stromal cells of other sources.

TL;DR: It is demonstrated that AMTC can block differentiation and maturation of monocytes into dendritic cells (DC), preventing the expression of the DC marker CD1a and reducing the expressionOf HLA-DR, CD80, and CD83, and the monocytic cells present in the amniotic mesenchymal region fail to differentiate toward the DC lineage.

TL;DR: The historical and current clinical applications of human placental tissues, and cells isolated from these tissues, are summarized, and some mechanisms thought to be responsible for the therapeutic effects observed after tissue and/or cell transplantation are discussed.

TL;DR: It is proved for the first time that the anti-proliferative effect is intrinsic to the amniotic membrane and cells derived thereof, since it is manifested in the absence of stimulating culture conditions, as opposed to MSC derived from the bone marrow, which possess an anti-Proliferatives ability only when cultured in the presence of activating stimuli.